Once-Daily Lirafugratinib Wins FDA Approval for Previously Treated Advanced Bile Duct Cancer Driven by FGFR2 Changes

FDA approves lirafugratinib (Lyrfigtu) for advanced bile duct cancer with FGFR2 changes after prior treatment. Who qualifies and key side effects.

Have A Referral?